Article
Dosing Begins in Phase 2b Study of Inhaled Therapy RT234 for PAH
Rating:
0.0
Views:
64
Likes:
1
Library:
1
A first patient in the U.S. has been dosed in a Phase 2b trial testing Respira Therapeutics' inhaled medicine-device combination product, called RT234, as a therapy for pulmonary arterial hypertension (PAH). The trial (NCT04266197), dubbed VIPAH-PRN, for Vardenafil Inhaled for Pulmonary Arterial...
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value